"pharmaceutical compositions comprising valsartan and nep inhibitors". The present invention relates to a pharmaceutical composition comprising a combination (i) of up to 1 valsartan antagonist or a pharmaceutically acceptable salt thereof and (ii) a nep inhibitor or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier and method for treating or preventing a condition or disease selected from the group consisting of hypertension, heart failure such as congestive heart failure (acute and chronic), left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial vibration, detrimental vascular remodeling, myocardial infarction and its sequelae, atherosclerosis, angina (whether unstable or stable), renal failure (diabetic and non-diabetic), heart failure, angina pectoris, diabetes, secondary aldosteronism, primary and secondary pulmonary hypertension, renal failure conditions such as diabetic nephropathy, glomerulonephritis, scleroderma, glomerular sclerosis, primary renal disease proteinuria and renal vascular hypertension, diabetic retinopathy, control of other vascular disorders such as migraine, peripheral vascular disease, raynaud's disease, luminal hyperplasia, cognitive dysfunction (such as alzheimer's), glaucoma and stroke, which comprises administering a therapeutically effective amount of the pharmaceutical composition to a mammal in need of such treatment."composições farmacêuticas que compreendem valsartan e inibidores de nep". a presente invenção refere-se a uma composição farmacêutica que compreende uma combinação (i) do antagonista de at 1 valsartan ou de um sal farmaceuticamente aceitável do mesmo e (ii) de um inibidor de nep ou de um sal farmaceuticamente aceitável do mesmo e opcionalmente um veículo farmaceuticamente aceitável e a um processo para o tratamento ou para a prevenção de uma condição ou doença selecio
